View Item 

Show simple item record

Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States
dc.contributor.authorBernstein, Elana J.
dc.contributor.authorAssassi, Shervin
dc.contributor.authorCastelino, Flavia V.
dc.contributor.authorChung, Lorinda
dc.contributor.authorCorreia, Chase
dc.contributor.authorEvnin, Luke B.
dc.contributor.authorFrech, Tracy M.
dc.contributor.authorGordon, Jessica K.
dc.contributor.authorSkaug, Brian A.
dc.contributor.authorHant, Faye N.
dc.contributor.authorHummers, Laura K.
dc.contributor.authorSandorfi, Nora
dc.contributor.authorShah, Ami A.
dc.contributor.authorShanmugam, Victoria K.
dc.contributor.authorSteen, Virginia D.
dc.contributor.authorKhanna, Dinesh
dc.date.accessioned2022-08-02T18:59:21Z
dc.date.available2023-08-02 14:59:19en
dc.date.available2022-08-02T18:59:21Z
dc.date.issued2022-07
dc.identifier.citationBernstein, Elana J.; Assassi, Shervin; Castelino, Flavia V.; Chung, Lorinda; Correia, Chase; Evnin, Luke B.; Frech, Tracy M.; Gordon, Jessica K.; Skaug, Brian A.; Hant, Faye N.; Hummers, Laura K.; Sandorfi, Nora; Shah, Ami A.; Shanmugam, Victoria K.; Steen, Virginia D.; Khanna, Dinesh (2022). "Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States." ACR Open Rheumatology 4(7): 596-602.
dc.identifier.issn2578-5745
dc.identifier.issn2578-5745
dc.identifier.urihttps://hdl.handle.net/2027.42/173148
dc.publisherWiley Periodicals, Inc.
dc.titleComputed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173148/1/acr211434.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173148/2/acr211434_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173148/3/acr211434-sup-0001-Disclosureform.pdf
dc.identifier.doi10.1002/acr2.11434
dc.identifier.sourceACR Open Rheumatology
dc.identifier.citedreferenceTyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809 – 15.
dc.identifier.citedreferenceSteen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940 – 4.
dc.identifier.citedreferencevan den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737 – 47.
dc.identifier.citedreferenceBernstein EJ, Khanna D, Lederer DJ. Screening high-resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: a global survey of rheumatologists. Arthritis Rheumatol 2018; 70: 971 – 2.
dc.identifier.citedreferenceSuliman YA, Dobrota R, Huscher D, Nguyen-Kim TD, Maurer B, Jordan S, et al. Brief Report: Pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 2015; 67: 3256 – 61.
dc.identifier.citedreferenceBernstein EJ, Jaafar S, Assassi S, Domsic RT, Frech TM, Gordon JK, et al. Performance characteristics of pulmonary function tests for the detection of interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2020; 72: 1892 – 6.
dc.identifier.citedreferenceElhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76: 1897 – 905.
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655 – 66.
dc.identifier.citedreferenceTashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4: 708 – 19.
dc.identifier.citedreferenceRoofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol 2021; 73: 1301 – 10.
dc.identifier.citedreferenceDistler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380: 2518 – 28.
dc.identifier.citedreferenceHoffmann-Vold AM, Fretheim H, Halse AK, Seip M, Bitter H, Wallenius M, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med 2019; 200: 1258 – 66.
dc.identifier.citedreferenceLarke FJ, Kruger RL, Cagnon CH, Flynn MJ, McNitt-Gray MM, Wu X, et al. Estimated radiation dose associated with low-dose chest CT of average-size participants in the National Lung Screening Trial. AJR Am J Roentgenol 2011; 197: 1165 – 9.
dc.identifier.citedreferenceFrech TM, VanBuren JM, Startup E, Assassi S, Bernstein EJ, Castelino FV, et al. Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures? Clin Rheumatol 2021; 40: 965 – 71.
dc.identifier.citedreferenceShanmugam VK, Frech TM, Steen VD, Hummers LK, Shah AA, Bernstein EJ, et al. Collaborative National Quality and Efficacy Registry (CONQUER) for scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. Clin Rheumatol 2020; 39: 93 – 102.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr211434.pdf
Size:
314.7KB
Format:
PDF
View/Open
Name:
acr211434_am.pdf
Size:
376.3KB
Format:
PDF
View/Open
Name:
acr211434-sup-0001-Disclosuref ...
Size:
1.518MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.